Omnicell (OMCL)
(Delayed Data from NSDQ)
$44.48 USD
-0.78 (-1.72%)
Updated Aug 30, 2024 03:59 PM ET
After-Market: $44.31 -0.17 (-0.38%) 7:58 PM ET
3-Hold of 5 3
B Value A Growth A Momentum A VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$44.48 USD
-0.78 (-1.72%)
Updated Aug 30, 2024 03:59 PM ET
After-Market: $44.31 -0.17 (-0.38%) 7:58 PM ET
3-Hold of 5 3
B Value A Growth A Momentum A VGM
Zacks News
Should SPDRSP6 SC (SLY) Be on Your Investing Radar?
by Zacks Equity Research
Style Box ETF report for SLY
Should SPDRSP6 SC (SLY) Be on Your Investing Radar?
by Zacks Equity Research
Style Box ETF report for SLY
Omnicell (OMCL) Inks New Deal to Manage Controlled Substances
by Zacks Equity Research
Omnicell (OMCL), Fresenius Kabi collaborate to offer safe and efficient dispensing of controlled substances across hospitals and health systems in the United States.
Globus Medical (GMED) Q3 Earnings Top Estimates, Revenues Lag
by Zacks Equity Research
Globus Medical (GMED) Q3 results reflect an estimated $12 million to $13 million in correlated revenue headwinds in the United States.
Zimmer Biomet (ZBH) Q3 Earnings Top Estimates, View Slashed
by Zacks Equity Research
Zimmer Biomet (ZBH) Q3 sales soft in Americas whereas EMEA and Asia-Pacific register growth at CER.
QIAGEN (QGEN) Q3 Earnings Surpass Estimates, 2021 View Up
by Zacks Equity Research
QIAGEN (QGEN) exited third-quarter 2021 with better-than-expected results on strength in the two major customer classes driving the top line.
Syneos Health (SYNH) Q3 Earnings Top Estimates, 2021 EPS View Up
by Zacks Equity Research
Syneos Health (SYNH) reports better-than-expected results for third-quarter 2021 on strength in Clinical Solutions and Commercial Solutions arms driving the top line.
Omnicell (OMCL) Q3 Earnings Top Estimates, 2021 View Up
by Zacks Equity Research
Growth across both the operating segments of Omnicell (OMCL) contributes to Q3 top-line growth.
NXGN or OMCL: Which Is the Better Value Stock Right Now?
by Zacks Equity Research
NXGN vs. OMCL: Which Stock Is the Better Value Option?
Omnicell (OMCL) Surpasses Q3 Earnings and Revenue Estimates
by Zacks Equity Research
Omnicell (OMCL) delivered earnings and revenue surprises of 18.68% and 4.43%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?
Medical Products Stock Earnings on Nov 2: IDXX, STE & More
by Urmimala Biswas
With the pandemic raging on, testing, vaccine and therapeutic makers are witnessing huge market adoption of their COVID-related support products in Q3.
Should iShares S&P SmallCap 600 Growth ETF (IJT) Be on Your Investing Radar?
by Zacks Equity Research
Style Box ETF report for IJT
Should You Invest in the Invesco S&P SmallCap Health Care ETF (PSCH)?
by Zacks Equity Research
Sector ETF report for PSCH
Omnicell (OMCL) Reports Next Week: Wall Street Expects Earnings Growth
by Zacks Equity Research
Omnicell (OMCL) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Omnicell (OMCL) Soars to 52-Week High, Time to Cash Out?
by Zacks Equity Research
Omnicell (OMCL) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.
Should SPDR S&P 600 Small Cap Growth ETF (SLYG) Be on Your Investing Radar?
by Zacks Equity Research
Style Box ETF report for SLYG
Quest Diagnostics (DGX) Q3 Earnings Top Estimates, View Up
by Zacks Equity Research
Quest Diagnostics (DGX) notes that in late summer it experienced some softness in the base business across the country but recovered in September.
Abbott's (ABT) Q3 Earnings Beat Estimates, 2021 Guidance Up
by Zacks Equity Research
Abbott's (ABT) COVID-19 testing-related sales in Q3 increase on demand for BinaxNOW, Panbio and ID NOW rapid testing platforms.
Intuitive Surgical (ISRG) Q3 Earnings Match Estimates, Up Y/Y
by Zacks Equity Research
Intuitive Surgical's (ISRG) third-quarter results reflect strong segmental performance.
CNVY vs. OMCL: Which Stock Should Value Investors Buy Now?
by Zacks Equity Research
CNVY vs. OMCL: Which Stock Is the Better Value Option?
Walgreens Boots (WBA) Q4 Earnings Top Estimates, Margins Up
by Zacks Equity Research
Walgreens Boots' (WBA) health and wellness sales increase for fiscal Q4 on growing demand for at-home COVID-19 tests and vitamins.
Should Vanguard S&P SmallCap 600 Growth ETF (VIOG) Be on Your Investing Radar?
by Zacks Equity Research
Style Box ETF report for VIOG
Should SPDR Portfolio S&P 600 Small Cap ETF (SPSM) Be on Your Investing Radar?
by Zacks Equity Research
Style Box ETF report for SPSM
Quidel Corporation (QDEL) Reports Solid Preliminary Q3 Revenues
by Zacks Equity Research
Quidel's (QDEL) revenue growth in the third quarter is likely to have been boosted by robust sales of its SARS-related products.
Catalent (CTLT) Expands Presence in Japan Via New Facility
by Zacks Equity Research
Catalent's (CTLT) new site is expected to become a key hub in its Asia-Pacific Clinical Supply Services network by significantly boosting its business.